ARGENX SE-ADR (ARGX) Earning Somewhat Positive News Coverage, Analysis Finds – StockNewsTimes

This post was originally published on this site

News stories about ARGENX SE-ADR (NASDAQ:ARGX) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ARGENX SE-ADR earned a daily sentiment score of 0.07 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.6254894019421 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Separately, Cowen and Company reaffirmed a “buy” rating on shares of ARGENX SE-ADR in a report on Thursday, August 24th.

ARGENX SE-ADR (NASDAQ ARGX) traded down 2.13% during mid-day trading on Wednesday, hitting $26.15. 70,991 shares of the stock were exchanged. ARGENX SE-ADR has a 52 week low of $17.33 and a 52 week high of $27.25. The stock’s market capitalization is $702.68 million. The company has a 50-day moving average of $22.01 and a 200-day moving average of $21.17.

COPYRIGHT VIOLATION WARNING: “ARGENX SE-ADR (ARGX) Earning Somewhat Positive News Coverage, Analysis Finds” was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at

ARGENX SE-ADR Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Receive News & Ratings for ARGENX SE-ADR Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ARGENX SE-ADR and related companies with’s FREE daily email newsletter.

This post was originally published on *this site*